Chantal Me E. Tallaksen

Prof. Dr. Chantal Me E. Tallaksen


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
MBM. I. Boldingh
M. I. Boldingh
LDL. Dekker
L. Dekker
AMA. H. Maniaol
A. H. Maniaol
CBC. Brunborg
C. Brunborg
ALA. F. Lipka
A. F. Lipka
CTChantal Me E. Tallaksen
Chantal Me E. Tallaksen
Current available therapies control Myasthenia gravis (MG) reasonably well, but Health Related Quality of life (HRQOL) remains lower than expected. The aim was provide insights in how HRQOL in MG stands across borders and time, compare the scores to general population controls and other chronic disorders and assess the impact of potential predictors for quality of life such as a) clinical characteristics b) antibodies c) thymoma and d) treatment in a population-based cohort. We designed a population-based cross-sectional study including 858 patients, 373 from Norway and 485 from the Netherlands. The Short Form Health Survey 36 (SF-36) and a cross-cultural validated questionnaire were used. Data were in addition compared to the general population, other chronic diseases and previous studies. Mean physical composite score was 59.4 and mental composite score 69.0 with no differences between the countries. The mean HRQOL score was lower in patients with bulbar and generalized symptoms (p < 0.001) compared to sex and age adjusted healthy controls, but not in patients with ocular symptoms or patients in remission. Multivariate analysis revealed that female gender, generalized symptoms and use of secondary immunosuppressive drugs at the time of testing were risk factors for reduced HRQOL. Remission and absence of generalized symptoms were favorable factors for HRQOL in MG patients. Historically, the HRQOL levels have not changed since 2001 and no new clinical predictors could be detected in this exhaustive population-based study. Further studies should explore the impact of non clinical factors like ethnic variations, socio-economic and hormonal factors on HRQOL.

26 September 2014 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
KHKetil Heimdal
Ketil Heimdal
MSMonica Sanchez-Guixé
Monica Sanchez-Guixé
IAIngvild Aukrust
Ingvild Aukrust
JBJens Bollerslev
Jens Bollerslev
OBOve Bruland
Ove Bruland
SJStefan Johansson
Stefan Johansson
A subset of hereditary cerebellar ataxias is inherited as autosomal recessive traits (ARCAs). Classification of recessive ataxias due to phenotypic differences in the cerebellum and cerebellar structures is constantly evolving due to new identified disease genes. Recently, reports have linked mutations in genes involved in ubiquitination (RNF216, OTUD4, STUB1) to ARCA with hypogonadism. With a combination of homozygozity mapping and exome sequencing, we identified three mutations in STUB1 in two families with ARCA and cognitive impairment; a homozygous missense variant (c.194A > G, p.Asn65Ser) that segregated in three affected siblings, and a missense change (c.82G > A, p.Glu28Lys) which was inherited in trans with a nonsense mutation (c.430A > T, p.Lys144Ter) in another patient. STUB1 encodes CHIP (C-terminus of Heat shock protein 70 – Interacting Protein), a dual function protein with a role in ubiquitination as a co-chaperone with heat shock proteins, and as an E3 ligase. We show that the p.Asn65Ser substitution impairs CHIP’s ability to ubiquitinate HSC70 in vitro, despite being able to self-ubiquitinate. These results are consistent with previous studies highlighting this as a critical residue for the interaction between CHIP and its co-chaperones. Furthermore, we show that the levels of CHIP are strongly reduced in vivo in patients’ fibroblasts compared to controls. These results suggest that STUB1 mutations might cause disease by impacting not only the E3 ligase function, but also its protein interaction properties and protein amount. Whether the clinical heterogeneity seen in STUB1 ARCA can be related to the location of the mutations remains to be understood, but interestingly, all siblings with the p.Asn65Ser substitution showed a marked appearance of accelerated aging not previously described in STUB1 related ARCA, none display hormonal aberrations/clinical hypogonadism while some affected family members had diabetes, alopecia, uveitis and ulcerative colitis, further refining the spectrum of STUB1 related disease.

2 February 2016 in Cerebellum & Ataxias
Verified
Journal Article
Open access
PDF file
JKJeanette Koht
Jeanette Koht
SLSven Olav Løstegaard
Sven Olav Løstegaard
IWIselin Wedding
Iselin Wedding
MVMarie Vidailhet
Marie Vidailhet
MLMalek Louha
Malek Louha
CTChantal Me E. Tallaksen
Chantal Me E. Tallaksen
Benign hereditary chorea is a rare disorder which is characterized by early onset, non-progressive choreic movement disturbance, with other hyperkinetic movements and unsteadiness also commonly seen. Hypothyroidism and lung disease are frequent additional features. The disorder is caused by mutations of the NKX2-1 gene on chromosome 14. A Norwegian four-generation family with eight affected was identified. All family members had an early onset movement disorder, starting before one year of age with motor delay and chorea. Learning difficulties were commonly reported from early school years. The family presented with choreic movements at rest, but other movements were seen; myoclonus, dystonia, ataxia, stuttering and tics-like movements. All patients reported unsteadiness and ataxic gait was observed in two patients. Videos are provided in the supplementary material. Most affected family members had asthma and a subclinical or clinical hypothyroidism. Sequencing revealed a mutation in the NKX2-1 gene in all eight affected family members. This is the first Norwegian family with benign hereditary chorea due to a mutation in the NKX2-1 gene, c.671 T > G (p.Leu224Arg). This family demonstrates well the wide phenotype, including dystonia, myoclonus and ataxia.

5 December 2016 in BMC Neurology
Verified
Journal Article
Open access
PDF file
CSCecilia Smith Simonsen
Cecilia Smith Simonsen
ECElisabeth Gulowsen Celius
Elisabeth Gulowsen Celius
CBCathrine Brunborg
Cathrine Brunborg
CTChantal Me E. Tallaksen
Chantal Me E. Tallaksen
EEErik Fink Eriksen
Erik Fink Eriksen
SMStine Marit Moen
Stine Marit Moen
Although disability is considered the main cause of low bone mineral density (BMD) in multiple sclerosis (MS), other factors related to the disease process or treatment could also be involved. The aim of this study was to assess whether patients with MS are more likely to develop low BMD (osteopenia or osteoporosis) than patients with the non-inflammatory neurological diseases Hereditary Spastic Paraplegia (HSP) and Hereditary Ataxia (HA). We performed a case control study comparing BMD (spine, hip and total body) and biochemical measures of bone metabolism in 91 MS patients and 77 patients with HSP or HA, matched for age, gender and disability. Both patient groups had lived with the disease for at least 10 years. In total 74.7% of the patients with MS and 75.3% of the patients with HSP or HA had osteopenia (−2.5 < T- score < −1.0) or osteoporosis (T- score ≤ −2.5) in one or more sites. Osteoporosis was more common in patients with MS than with HSP/HA (44.0 vs 20.8%, p =0.001). This difference was not significant after correction for confounders (p = 0.07), nor were any of the biochemical markers. Most patients with disabling neurological diseases like MS and HSP/HA develop osteopenia or osteoporosis. MS patients had osteoporosis more frequently than HA/HSP patients, though the difference was not significant after adjusting for confounders. Osteoporosis and bone health should be considered in all patients with both inflammatory and degenerative chronic neurological diseases.

29 November 2013 in BMC Neurology
Verified
Journal Article
Open access
PDF file
IWIselin Marie Wedding
Iselin Marie Wedding
JKJeanette Koht
Jeanette Koht
EDEspen Dietrichs
Espen Dietrichs
NLNils Inge Landrø
Nils Inge Landrø
CTChantal Me E. Tallaksen
Chantal Me E. Tallaksen
There is an increasing awareness of the role of the cerebellum not only in motor, but also in cognitive and emotional functions. Spinocerebellar ataxia type 14 (SCA14) is an autosomal dominant hereditary ataxia characterized by a relatively pure cerebellar phenotype. Cognitive impairment has been reported in studies with phenotype descriptions of SCA14, but previous studies have been small without control groups, and no homogeneous and systematic test panel has been used. The objective of this study was to thoroughly characterize the neuropsychological profile in ten Norwegian SCA14 subjects compared to unaffected family members and population norm data.

29 October 2020 in Journal of the Neurological Sciences
Verified
Journal Article
Open access
PDF file
SPSjur Prestsæter
Sjur Prestsæter
JKJeanette Koht
Jeanette Koht
FLFoudil LAMARI
Foudil LAMARI
CTChantal Me E. Tallaksen
Chantal Me E. Tallaksen
SHStian Tobias Juel Hoven
Stian Tobias Juel Hoven
SRSiri Lynne Rydning
Siri Lynne Rydning
• Hereditary spastic paraplegia SPG5 is a rare neurodegenerative disorder. • Plasma hydroxycholesterols are elevated in patients with SPG5. • Plasma hydroxycholesterols are useful diagnostic biomarkers for SPG5. • Cortical sensory evoked responses may be absent in SPG5. • SPG5 is one of few neurodegenerative disorders with promising new treatment options.